Form 4: TG Therapeutics CEO Michael Weiss Receives 750,000 Restricted Shares

TG Therapeutics CEO Michael Weiss was granted 750,000 restricted shares that will vest based on the company's total shareholder return compared to the Nasdaq Biotechnology Index over various periods.

Summary

• Michael S. Weiss, CEO of TG Therapeutics, received 750,000 restricted shares on January 29, 2025.
• These shares will vest on the first anniversary of when TG Therapeutics' total shareholder return (TSR) exceeds the TSR of the Nasdaq Biotechnology Index (NBI) over a 3, 5, 7, or 9-year period.
• Following this transaction, Weiss beneficially owns 13,824,929 shares of TG Therapeutics, including previously granted restricted shares that vest over various time periods.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice with performance-based incentives, which is generally viewed positively. The long-term vesting period suggests a focus on sustained growth.

Positives

• The vesting structure of the restricted shares aligns management's interests with long-term shareholder value creation.
• The performance-based vesting criteria could incentivize the CEO to drive strong company performance.

Risks

• The vesting of the shares is dependent on the company's performance relative to the Nasdaq Biotechnology Index, which is subject to market fluctuations and industry-specific risks.
• If the company's TSR does not outperform the NBI over the specified periods, the shares will not vest.

Future Outlook

The vesting of the restricted shares is contingent on future performance relative to the Nasdaq Biotechnology Index over the next 3 to 9 years.

Industry Context

The use of performance-based equity compensation is a common practice in the biotechnology industry to align management's interests with shareholder value creation. The specific vesting conditions tied to outperforming the Nasdaq Biotechnology Index are designed to incentivize long-term growth and outperformance.

Comparison to Industry Standards

• Many biotechnology companies use similar performance-based equity grants to incentivize executives.
• The use of a benchmark like the Nasdaq Biotechnology Index is a common practice to measure relative performance.
• Companies like Gilead Sciences, Amgen, and Biogen also use similar long-term incentive plans tied to performance metrics.

Stakeholder Impact

• Shareholders may view the performance-based vesting as a positive sign that management is incentivized to drive long-term value.
• Employees may see this as a sign of confidence in the company's future prospects.

Key Dates

Keywords

restricted shares, shareholder return, TSR, Nasdaq Biotechnology Index, NBI, vesting, CEO, Michael Weiss, TG Therapeutics, equity compensation